Clinical Trial Update: Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous Newnorm human immunoglobulin in patients with primary imm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• Newnorm (human immunoglobulin)

Snippet

Sponsor: Octapharma | Conditions: Primary Immune Deficiency | Phase 3 | Status: ACTIVE_NOT_RECRUITING